PharmaEssentia Corporation
Research PharmaEssentia Corporation (6446.TW) on Bullrun: market cap TWD 552.31B, P/E 76.9, dividend yield 0.1%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker6446.TW
- ExchangeTW
- CountryTaiwan
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyTWD
- Market capTWD 552.31B
- P/E76.9
- Dividend yield0.1%
- Financial periodQ2 2026
- RevenueTWD 6.86B
- Net incomeTWD 2.53B
- Free cash flowTWD 2.01B
- Gross margin94.2%
Valuation Snapshot
latest market cap is TWD 552.31B; P/E is 76.9; dividend yield is 0.1%.
Peer valuation comparison
Latest P/E is 76.86x versus a Healthcare sector median of 21.8x (252.6% above).
Latest dividend yield is 0.11% versus a Healthcare sector median of 2.4% (95.4% below).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-11-11 | TWD 552.31B | 76.9 | 0.1% | 1.49 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 1.49 TWD, yield 0.1%.
About PharmaEssentia Corporation
PharmaEssentia Corporation, a biopharmaceutical company engages in medicine discovery, supplements in developing specialty pharmaceutical reagents, API, and new drug patterns developments in the Americas, Europe, Asia, and Taiwan. Its products include BESREMi, an interferon therapy indicated for polycythemia vera, essential thrombocythemia, PMF, and adult T-cell leukemias. The company also develops Ropeg + anti PD-1; PEG-IL-2 (P11838); PEG-Cytokines; PD-1-IL-2v; ADC; ADCS; NY-ESO-1 TCR-T;
ETFs that hold PharmaEssentia Corporation
PharmaEssentia Corporation is one of the ten largest holdings of one ETF that investors in Europe can buy:
| ETF | Weight | TER |
|---|---|---|
| iShares Ageing Population UCITS ETF USD (Acc) | 0.81% | 0.40% |
US-listed ETFs
PharmaEssentia Corporation is held by 58 US-listed ETFs, going by the latest portfolios they filed with the SEC. The 8 most traded of them:
| ETF | Weight | Fee |
|---|---|---|
| iShares MSCI Emerging Markets ETF (EEM) | 0.07% | 0.72% |
| iShares Core MSCI Emerging Markets ETF (IEMG) | 0.06% | 0.09% |
| iShares MSCI Taiwan ETF (EWT) | 0.64% | 0.59% |
| Vanguard Total International Stock Index Fund ETF Shares (VXUS) | 0.02% | 0.05% |
| Vanguard FTSE Emerging Markets Index Fund ETF Shares (VWO) | 0.09% | 0.06% |
| Vanguard Total World Stock Index Fund ETF Shares (VT) | 0.01% | 0.06% |
| iShares MSCI ACWI ETF (ACWI) | 0.01% | 0.32% |
| iShares MSCI ACWI ex U.S. ETF (ACWX) | 0.03% | 0.32% |
Portfolios as filed with the SEC on Form N-PORT, dated May to July 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is PharmaEssentia Corporation's market cap?
PharmaEssentia Corporation's market capitalization is TWD 552.31B.
What is PharmaEssentia Corporation's P/E ratio?
PharmaEssentia Corporation's price-to-earnings (P/E) ratio is 76.9.
Does PharmaEssentia Corporation pay a dividend?
PharmaEssentia Corporation has a dividend yield of 0.1%.
What does PharmaEssentia Corporation do?
PharmaEssentia Corporation, a biopharmaceutical company engages in medicine discovery, supplements in developing specialty pharmaceutical reagents, API, and new drug patterns developments in the Americas, Europe, Asia, and Taiwan. Its products include BESREMi, an interferon therapy indicated for polycythemia vera, essential thrombocythemia, PMF, and adult T-cell leukemias. The company also develops Ropeg + anti PD-1; PEG-IL-2 (P11838); PEG-Cytokines; PD-1-IL-2v; ADC; ADCS; NY-ESO-1 TCR-T; and Novel TCR-T for the treatment of solid tumor and immunology.